Detailed Coverage

Alembic Pharmaceuticals Secures USFDA Approval for Prucalopride Tablets

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, in 1 mg and 2 mg strengths.

Reader Takeaway: USFDA approval offers new revenue stream; Generic drug market size is key.

What just happened

Alembic Pharmaceuticals announced it has secured final approval from the USFDA for Prucalopride Tablets, a generic version of Motegrity Tablets. These tablets are indicated for treating chronic idiopathic constipation (CIC) in adults.

The drug will be available in 1 mg and 2 mg strengths. This approval marks a significant addition to Alembic's US generic product portfolio.

Why this matters

The approval allows Alembic to market a generic version of the reference listed drug in the lucrative US market. According to IQVIA data, the addressable market for Prucalopride Tablets was estimated at US$ 100 million for the twelve months ending March 2026.

This provides a clear, quantifiable revenue opportunity for the company and demonstrates its ability to navigate complex US regulatory pathways.

The backstory

Alembic Pharmaceuticals has a strong track record with the USFDA, contributing to its cumulative regulatory approvals. As of the latest update, the company holds 245 cumulative ANDA approvals, with 225 being final and 20 tentative.

This consistent regulatory success supports its strategy of expanding its generic product offerings in international markets, particularly the US.

What changes now

Alembic Pharmaceuticals can now launch Prucalopride Tablets in the US market, directly competing with the innovator drug. The company will leverage its established market presence and field force to drive sales.

This approval is expected to contribute to the company's revenue growth in the US generics segment.

Risks to watch

While the approval is positive, investors should monitor Alembic's ability to convert its large number of cumulative ANDA approvals into consistent revenue. Competition in the generic drug market can also impact pricing and profitability.

Sustaining regulatory compliance across all manufacturing facilities remains a critical factor for continued market access.

Peer comparison

(No specific peer comparison data is available in the filing. Generally, pharmaceutical companies with strong R&D and regulatory capabilities often compete in the US generics market.)

Context metrics (time-bound)

• Addressable Market: US$ 100 million (12 months ending March 2026).
• Cumulative USFDA ANDA Approvals: 245 total (225 final, 20 tentative).

What to track next

Investors should track the sales performance of Prucalopride Tablets post-launch and Alembic's pipeline of upcoming generic drug approvals and launches in the US.

Monitoring the company's overall revenue growth and profitability, especially from its international generics business, will be key.